Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telithromycin Effectiveness in CAP and AECB
NCT00546676Phase 4Completed
- Sponsor
- Sanofi
- Start
- May 2004
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of telithromycin in community acquired pneumonia (CAP) and chronic bronchitis (CB), sponsored by Sanofi. Primary endpoint: Clinical Effectiveness (Cure Rates). Started May 2004; status: completed.
02
Drugs
telithromycin
03
Conditions
community acquired pneumonia (CAP)chronic bronchitis (CB)
Beyond the preview
Go deeper on NCT00546676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00546676.